Search Results

You are looking at 51 - 60 of 825 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016

Steven M. Horwitz, Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar, and Pierluigi Porcu

Second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant (SCT), based on the patient's eligibility for transplant, is the standard treatment approach for patients with relapsed or refractory disease. The management of patients

Full access

Updates in Treatment Strategies for Hodgkin Lymphoma

Ranjana H. Advani

Given the myriad of treatment options available for frontline treatment of advanced-stage Hodgkin lymphoma (HL) and for relapsed HL, clinicians must evaluate the advantages and disadvantages of each regimen, balancing risk with benefit for the

Full access

Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond

Jae Park

cell transplant (HSCT). At the NCCN 2019 Annual Congress: Hematologic Malignancies, Jae Park, MD, Associate Attending Physician, Memorial Sloan Kettering Cancer Center, summarized key studies of novel immunotherapies in relapsed/refractory (R/R) ALL and

Full access

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Robert Chen, Bouthaina Dabaja, Robert Dean, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Kami Maddocks, David G. Maloney, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Rachel Rabinovitch, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

the reduction of long-term toxicity. However, 10% to 20% 3 – 6 of patients with favorable features and early-stage disease and up to 30% 7 , 8 with advanced-stage disease experience relapse. The standard treatment option for chemosensitive patients

Full access

Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Jennifer R. Brown

—typically obinutuzumab in the frontline setting and rituximab in the relapsed setting,” Dr. Brown noted at the NCCN 2021 Virtual Congress: Hematologic Malignancies. “But we still, nonetheless, have many unanswered questions.” According to Dr. Brown, current efforts in

Full access

BIO23-022: Adding Virtual Reality Mindful Exposure Therapy to a Cancer Center’s Tobacco Treatment Offerings: An Acceptability Pilot Study

Riley Walton Jackson, Ann Cao-Nasalga, Amy Chieng, Amy Pirkl, Annemarie D. Jagielo, Cindy Tran, Emilio Goldenhersch, Nicolas Rosencovich, Cristian Waitman, and Judith J. Prochaska

50% or more, and two quit for 24-hours then relapsed; 3 (33%) reported some dizziness with app use; 7 of 9 (77%) would recommend MindCotine to a friend. Conclusions: In an acceptability pilot study of a novel VR-MET tobacco treatment app offered to

Full access

Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Anthony J. Olszanski

Patients with stage III melanoma are at high risk for disease recurrence, but adjuvant therapy—including targeted therapy and immunotherapy—may prevent or delay relapse, according to Anthony J. Olszanski, MD, RPh, Associate Professor and Vice Chair

Full access

Multiple Myeloma, Version 1.2013

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Cristina Gasparetto, Francisco Hernandez-Illizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Michael Liedtke, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Furhan Yunus, Dorothy A. Shead, and Rashmi Kumar

responsible for MM has led to the development of novel agents. The availability of many novel evidence-based options for the treatment of MM has led to significant improvements in response and survival. Most patients with MM experience relapse or become

Full access

Updates in the Treatment of Multiple Myeloma

Presented by: Shaji K. Kumar

diagnosis for patients with active myeloma that needs treatment, and to incorporate risk stratification, which is critical in terms of deciding upon the overall treatment goals and approaches over time . . . . Unfortunately, patients continue to relapse. We

Full access

In Defense of Hepatic Arterial Infusion for Hepatic Metastases of Colorectal Cancer

Nancy Kemeny

infusion. Results were compared with those of 125 consecutive patients who received adjuvant folfox or folfiri after resection with a median follow-up of 43 months. Abbreviations: FUDR, floxuridine; HAI, hepatic arterial infusion; RFS, relapse